Integra LifeSciences (NASDAQ:IART) Upgraded at Argus

Argus upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a research note released on Monday, MarketBeat reports.

Separately, Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Trading Up 1.4 %

IART stock opened at $21.99 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -244.31, a PEG ratio of 0.73 and a beta of 1.23. The business has a fifty day simple moving average of $23.74 and a 200-day simple moving average of $22.24. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $35.45.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share. On average, equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Large investors have recently bought and sold shares of the company. Quadrant Capital Group LLC boosted its stake in shares of Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares in the last quarter. Covestor Ltd increased its position in shares of Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter worth about $180,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.